• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Veranova: A CDMO that manages complexity with confidence.

    MTTI 225Ac-EBTATE Effective Against Neuroendocrine Tumors

    BUSINESSWIRE

    MTTI Reports On Fast-Acting Tumor Visualization Molecule

    BUSINESSWIRE

    MTTI At 2nd Targeted Radionuclide Pharmaceuticals Summit

    BUSINESSWIRE

    MTTI Reports On 225Ac/177Lu-EBTATE Radiopharmaceuticals At SNMMI 2024

    BUSINESSWIRE

    Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer

    BUSINESSWIRE

    MTTI Highlights Promising One-Year Follow-Up on EBTATE Treatment

    BUSINESSWIRE

    MTTI Announces Favorable 3Y Follow-Up for EBTATE in Neuroendocrine Tumors

    BUSINESSWIRE

    MTTI Doses First Patient in EBTATE Neuroendocrine Tumor Clinical Trial

    BUSINESSWIRE

    MTTI Announced the Chinese Approval for a Rabies Drug

    BUSINESSWIRE

    MTTI and Monrol sign supply agreement for the clinical material Lu-177 nca

    WORLD-TODAY-NEWS

    Molecular Targeting Technologies Announces Spray Technology

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.